Bli medlem
Bli medlem

Du är här


Q-linea: Redeye initiates coverage of Q-linea

Q-linea is about 12 months from launching ASTar - a diagnostic system
for rapid phenotypic antibiotic susceptibility testing (AST). The
share's underperformance indicates that investors have yet to grasp
the technology's paradigm-shifting impact and the product portfolio's
high sales potential.

Read more and download the research update:

Start following companies at Redeye to receive the latest equity
research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment


Författare Cision

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.